Skip to main content

Primary Immunodeficiency Disease

2
Pipeline Programs
5
Companies
5
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
2
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

5 companies ranked by most advanced pipeline stage

Biocorp
BiocorpFrance - Issoire
1 program
1
Boya IVIGPhase 31 trial
Active Trials
NCT06150833Unknown50Est. Sep 2025
Syneos Health
Syneos HealthNC - Morrisville
1 program
1
IgG Next GenerationPhase 3
Octapharma
OctapharmaAustria - Vienna
2 programs
NewGamPHASE_31 trial
16,5% CutaquigPHASE_41 trial
Active Trials
NCT01313507Completed21Est. Sep 2012
NCT03677557Unknown30Est. Aug 2021
Takeda
TakedaTOKYO, Japan
1 program
IGSC 20% infusionPHASE_31 trial
Active Trials
NCT04842643Completed12Est. Apr 2024
Biotest Pharmaceuticals
Biotest PharmaceuticalsGermany - Dreieich
1 program
IgG Next GenerationPHASE_31 trial
Active Trials
NCT02810444Completed81Est. Apr 2020

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Octapharma16,5% Cutaquig
BiocorpBoya IVIG
TakedaIGSC 20% infusion
Biotest PharmaceuticalsIgG Next Generation
OctapharmaNewGam

Clinical Trials (5)

Total enrollment: 194 patients across 5 trials

NCT03677557Octapharma16,5% Cutaquig

Safety, Tolerability, Patient Satisfaction and Cost of 16.5% Subcutaneous Immunoglobulin (Cutaquig®) Treatment

Start: Sep 2018Est. completion: Aug 202130 patients
Phase 4Unknown
NCT06150833BiocorpBoya IVIG

Efficacy and Safety and Pharmacokinetics of Boya IVIG

Start: Apr 2024Est. completion: Sep 202550 patients
Phase 3Unknown
NCT04842643TakedaIGSC 20% infusion

An Extension Study of TAK-664 for Japanese People With Primary Immunodeficiency Disease

Start: Apr 2021Est. completion: Apr 202412 patients
Phase 3Completed
NCT02810444Biotest PharmaceuticalsIgG Next Generation

Study to Investigate Efficacy, Safety and Pharmacokinetics of BT595 in Subjects With PID

Start: Oct 2016Est. completion: Apr 202081 patients
Phase 3Completed
NCT01313507OctapharmaNewGam

High Infusion Rate Study of Immunoglobulin Intravenous (Human) 10% (NewGam)

Start: May 2011Est. completion: Sep 201221 patients
Phase 3Completed

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

2 late-stage (Phase 3) programs, potential near-term approvals
5 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.